ClinicalTrials.gg
Status unknownNCT05600010Updated Nov 2, 2022

Detection of Microplastics in Cardiac Surgery Patients

An observational study in Cardiac Surgery, Microplastics and Nanoplastics, sponsored by Kun Hua. Status unknown. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Kun Hua · Observational

How we know

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
40
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The exponential growth in plastic production/use translates into a parallel increase in environmental plastic waste, which is constantly degraded into microplastics and nanoplastics. Information on the effects of microplastics on human health is still preliminary.

Cardiac surgery patients is a population high exposed to plastics. This observational study will obtain biological samples of cardiac surgery patients as a reference and vulnerable group of individuals highly exposed to microplastics and potentially more susceptible.

The objective of this research is to be able to detect microplastics on blood and operation samples of cardiac surgery patients as well as their potential genotoxic and immunological damage.

02

Conditions studied

  • Cardiac Surgery
  • Microplastics
  • Nanoplastics
  • Cardiovascular Diseases
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 40 is below the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Kun Hua is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cardiac surgery patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Elective cardiac surgery

Exclusion criteria

Exclusion Criteria:

  • Emergency surgery or limited-term surgery
  • Previous cardiac surgery
  • Previous severe liver disease
  • Pregnant or planning to become pregnant
  • Have a malignant tumor
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Study group

    Detection of microplastics/nanoplastics in heart tissue and the blood of patients undergoing cardiac surgery

    Other: Microplastics

Interventions

  • OtherMicroplastics

    Detection of microplastics as a yes/no value

06

What researchers measure

Primary outcomes

  1. Detection of microplastics in human heart tissue and the blood

    Detection of microplastics in human heart tissue and the blood undergoing cardiac surgery

    Time frame: perioperative: preoperative and pro-/postoperative blood and intraoperative heart tissue

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2022; primary completion for May 2023, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Oct 31, 2022
StartEst.
Nov 1, 2022
Primary completionEst.
May 31, 2023
CompletionEst.
Oct 22, 2023
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05600010
Lead sponsor
Kun Hua
Responsible party
Kun Hua (Deputy Chief Surgeon, Beijing Anzhen Hospital) — Sponsor-investigator
First posted
Oct 31, 2022
Start date
Nov 1, 2022 (estimated)
Primary completion
May 31, 2023 (estimated)
Completion
Oct 22, 2023 (estimated)
Last update
Nov 2, 2022

Study contacts

Kun Hua, M.D.
Contact
huakun0310@126.com
+8615810111206
Kun Hua
study chair · Beijing Anzhen Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion